A Scientific Journey Towards Translational Therapeutic Discovery
Toluwase Fatoki is a bioscientific and computational drug-discovery business entity whose work focuses on understanding molecular interactions, investigating disease-associated biological processes and identifying potential therapeutic candidates.
Toluwase Fatoki’s academic and research background spans biochemistry, chemistry, molecular biophysics, computational biology and pharmacological investigation.
We have developed research experience in molecular docking, molecular dynamics simulations, computational pharmacology, peptide research, bioinformatics and the analysis of molecular interactions.
Our scientific interests are driven by a fundamental question:
How can we translate our understanding of molecular biology into better therapeutic possibilities for complex human diseases?
This question increasingly defines our research direction, particularly our interest in amyotrophic lateral sclerosis.
Academic Background
Toluwase Fatoki’s academic training includes undergraduate and postgraduate education in biochemistry, followed by graduate-level research in chemistry and biophysical sciences.
This multidisciplinary foundation has shaped our approach to scientific investigation, allowing me to connect biochemical mechanisms with molecular structures, computational predictions and experimental observations.
Toluwase Fatoki’s research development has involved both computational and experimental perspectives, with particular interests in protein structure and function, peptide interactions, molecular stability and the molecular basis of disease.
Research Experience and Scientific Interests
Our research experience includes:
- Computational investigation of potential therapeutic compounds for neurodegenerative diseases.
- Molecular docking and protein–ligand interaction analysis.
- Molecular dynamics simulations of biological systems.
- Molecular modelling and biophysical characterisation of peptides.
- Bioinformatics and computational analysis of disease-associated molecular targets.
- Investigation of protein stability, aggregation and molecular interactions.
- Pharmacological assessment of potential therapeutic compounds.
Our work on bioactive peptides discovery has also contributed to my interest in understanding how molecular structure, electrostatic interactions, solvent conditions and biomolecular environments influence biological activity.
These experiences provide a foundation for investigating the molecular behaviour of disease-associated proteins and potential therapeutic molecules.
Why ALS Drug Discovery?
Amyotrophic lateral sclerosis is a complex neurodegenerative disease involving progressive degeneration of motor neurons.
Despite significant advances in understanding ALS biology, therapeutic development remains challenging. The disease involves interconnected pathological processes, including protein aggregation, RNA dysregulation, mitochondrial dysfunction, impaired cellular metabolism, neuroinflammation and disturbances in neuronal homeostasis.
Furthermore, ALS is biologically heterogeneous. Different genetic and molecular mechanisms may contribute to disease development and progression in different patient populations.
We believe that meaningful progress will require integrated therapeutic discovery strategies that consider this biological complexity.
Our research therefore focuses on identifying molecular targets, discovering therapeutic candidates and investigating combinations of interventions that may address complementary disease mechanisms.
Our Scientific Philosophy
Biology before computation.
Computational tools are valuable when they address meaningful biological questions. Predictions should be guided by disease mechanisms and biological evidence.
Molecular evidence before therapeutic claims.
Docking scores and molecular dynamics simulations are not proof of therapeutic efficacy. Candidate molecules require appropriate biochemical, biophysical and cellular investigation.
Collaboration before isolation.
ALS drug discovery requires expertise across neuroscience, molecular biology, chemistry, pharmacology, biophysics and clinical research. We believe multidisciplinary partnerships are essential.
Translation as the ultimate objective.
The long-term purpose of my research is to contribute to discoveries that can eventually inform better therapeutic strategies for ALS.
Long-Term Vision
We aim to develop a multidisciplinary research programme dedicated to integrated ALS drug discovery, combining computational approaches with experimental validation and translational research partnerships.
Ultimately, we hope to contribute to the development of more precise, biologically informed and effective therapeutic strategies for ALS.
